巴瑞替尼在皮肤科的超适应证使用。

Off-Label Use of Baricitinib in Dermatology.

出版信息

J Drugs Dermatol. 2023 Aug 1;22(8):795-801. doi: 10.36849/jdd.7360.

Abstract

The current US Food and Drug Administration (FDA) indications for baricitinib include alopecia areata, rheumatoid arthritis, and COVID-19. However, increasing evidence indicates that baricitinib is effective in treating a variety of dermatological conditions. This review article comprehensively presents the available literature on this topic and will be of interest to practitioners in the field. These disorders may be broadly classified as connective tissue diseases, eczematous dermatoses, alopecias, vascular disorders, granulomatous diseases, neutrophilic dermatoses, vitiligo, psoriasis, lichenoid disorders, and other miscellaneous disorders. Shah A, Yumeen S, Qureshi A, et al. Off-label use of baricitinib in dermatology. J Drugs Dermatol. 2023;22(8):795-801. doi:10.36849/JDD.7360.

摘要

巴瑞替尼目前在美国食品药品监督管理局（FDA）的适应证包括斑秃、类风湿关节炎和 COVID-19。然而，越来越多的证据表明，巴瑞替尼在治疗多种皮肤科疾病方面有效。这篇综述文章全面介绍了这一主题的现有文献，对该领域的从业者将具有参考价值。这些疾病大致可分为结缔组织疾病、湿疹性皮肤病、脱发、血管疾病、肉芽肿性疾病、中性粒细胞皮肤病、白癜风、银屑病、苔藓样疾病和其他杂类疾病。Shah A、Yumeen S、Qureshi A 等人。巴瑞替尼在皮肤科的适应证外使用。《皮肤病药物杂志》。2023;22(8):795-801.doi:10.36849/JDD.7360.